• Product NameFedratinib (SAR302503, TG101348)
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityFedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Phase 2.
• Target Namec-RET inhibitor; FLT inhibitor; JAK inhibitor
• CAS No. 936091-26-8
• Calculated MW 524.68
• Formulation C27H36N6O3S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Other
  SMILES:CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC(=CC=C1)S(=O)(=O)NC(C)(C)C
  Pathways:Angiogenesis; Apoptosis; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors; JAK/STAT signaling; Stem Cells
  Receptor:RET; FLT3; JAK2; JAK2 (V617F)
  Boling pt:
  Melting pt:
  Solubility:DMSO: 100 mg/mL (190.59 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Wernig G, et al. Y Cell, 2008, 13(4), 311-320.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting